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Number of medicationsAbstract Increased length of stay (LOS) in the hospital incurs substantial ﬁnancial costs on the
healthcare system. Multiple factors are associated with LOS. However, few studies have been done
to associate the impact of Total Daily Doses (TDD) and LOS. Hence, the aim of this study is to
examine the association between patients’ LOS upon readmission and their TDD before readmis-
sion. A retrospective cross-sectional study of readmission cases occurring from 1st January to 31st
March 2013 was conducted at a regional hospital. Demographics and clinical variables were col-
lected using electronic medical databases. Univariable and multiple linear regressions were used.
Confounders such as comorbidities and drug related problems (DRP) were controlled for in this
study. There were 432 patients and 649 readmissions examined. The average TDD and LOS were
18.04 ± 8.16 and 7.63 days ± 7.08 respectively. In the univariable analysis, variables that were sig-
niﬁcantly associated with the LOS included age above 75 year-old, race, comorbidity, number of
comorbidities, number of medications, TDD and thrombocytopenia as DRPs. In the multiple linear
regression, there was a statistically signiﬁcant association between TDD (b= 0.0733, p= 0.030)
and LOS. Variables that were found signiﬁcant were age above 75 year-old (b= 1.5477,
p= 0.008), Malay (b= 1.5123, p= 0.033), other races (b= 2.6174, p= 0.007), depression
Total Daily Doses and length of stay 389(b= 2.1551, p= 0.031) and thrombocytopenia as a type of DRP (b= 7.5548, p= 0.027). When
TDD was replaced with number of medications, number of medications (b= 0.1487, p= 0.021),
age of 75 year-old (b= 1.5303, p= 0.009), Malay (b= 1.4687, p= 0.038), race of others
(b= 2.6499, p= 0.007), depression (b= 2.1951, p= 0.028) and thrombocytopenia as a type
of DRP (b= 7.5260, p= 0.028) were signiﬁcant. In conclusion, a signiﬁcant relationship between
TDD and number of medications before readmission and the LOS upon readmission was estab-
lished. This ﬁnding highlights the importance of optimizing patients’ TDD in the attempt of reduc-
ing their LOS.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Length of stay (LOS) is deﬁned as the number of bed days in
each inpatient episode (Berki et al., 1984). It has been identi-
ﬁed to be one of the main indicators of hospital performance
and patients’ consumption of resources (Berki et al., 1984;
Becker et al., 1980; Kulinskaya et al., 2005). In Singapore,
the mean LOS in the public acute care hospitals is 5.8 days
in 2012 (Hospital Services, 2013). Based on the 2012 data,
most patients were admitted into the hospital due to accident,
poisoning and violence (8.3%), cancer (6.0%) or ischemic
heart disease (3.6%) Top 10 Conditions of Hospitalisation,
2014. The national healthcare expenditure constitutes about
4% of Singapore Gross Domestic Product (GDP) in 2013
and is projected to increase as the population ages (Costs
and Financing, 2014).
In 2011, healthcare expenditures constituted about 18 per-
cent of the Gross Domestic Product (GDP) in the United
States (Pfuntner et al., 2011). As an important variable con-
tributing to cost, increased LOS exerts substantial ﬁnancial
burden on the healthcare system. Extensive studies have also
found that reduction in LOS is associated with cost savings.
National Health Service (NHS) Institute for Innovation and
Improvement in the United Kingdom projected an annual sav-
ing of approximately £8 million if the average LOS was short-
ened by one day (Length of Stay – Reducing Length of Stay,
2008). A study conducted in the United States also showed
that with a 1-day and 2-day reduction in LOS, the estimated
cost savings could amount to $680 and $1408 respectively
(Fine et al., 2000). Reducing LOS will increase the capacity
such as inpatient beds and manpower in the healthcare system,
improving its productivity and efﬁciency (Length of Stay –
Reducing Length of Stay, 2008). Besides, with an increase in
LOS, unplanned rehospitalization and a rise in the adverse
drug reactions of all severities could be resulted (Lazarou
et al., 1998; Morandi et al., 2013). A 6.1% probability of
adverse drug reactions, 20.6% probability of infections and
2.5% probability of ulcers were correlated with a LOS of
8 days 7 nights (Hauck and Zhao, Dec 2011). As patients’
LOS increase, patients are exposed to a greater risk of an
adverse event (Hauck and Zhao, Dec 2011). LOS therefore,
has notable implications on patients’ health and the usage of
healthcare resources.
While physician and hospital affect LOS, patient character-
istics and their medications prior to hospitalization play signif-
icant roles in inﬂuencing LOS as well (Berki et al., 1984;
Lawton andWholey, 1991; Wuerz and Meador, 1992). A study
on the medication use in Singapore nursing homes found thaton average, the residents were on 5.32 medications (Mamun
et al., 2004). Patients’ extended LOS due to drug related causes
are often preventable and their drug related problems (DRPs)
can be attributed to polypharmacy (Viktil et al., Feb 2007;
Colley and Lucas, 1993). Non-compliance, a commonly cited
DRP can be ameliorated through the reduction of pill burden
and simpliﬁcation of regimens (Colley and Lucas, 1993).
Although the reduction of pill burden could potentially
improve patients’ disease control and thereby lead to a reduc-
tion in LOS, no direct association has been clearly shown
between such an intervention and LOS. Furthermore, previous
studies had presented varied responses on the relationship of
polypharmacy and LOS (Nobili et al., 2011; Campbell et al.,
2004; Incalzi et al., Mar 1992). Studies conducted by Campbell
et al. and Incalzi et al. showed that polypharmacy is signiﬁ-
cantly related to extended LOS (Campbell et al., 2004;
Incalzi et al., 1992). On the other hand, Nobili et al. suggested
otherwise as polypharmacy was found to be unrelated to LOS
in their study (Nobili et al., 2011).
2. Aim of the study
Our study aimed to explore the association between patients’
pill burden, more speciﬁcally in terms of Total Daily Doses
(TDD) and their LOS upon readmission. We hypothesized
that higher TDD is associated with longer patient’s LOS,
potentially due to non-compliance.
3. Methods
3.1. Study design
A retrospective, cross-sectional study was conducted at a
regional hospital in Singapore. This study was performed using
the electronic medical databases shared by healthcare institu-
tions across Singapore.
Institutional board review and waiver of patients’ written
informed consent were obtained from the National Healthcare
Group, Singapore.
3.2. Subjects
Patients aged above 18 who were ﬁrst admitted to the regional
hospital and subsequently readmitted to any healthcare institu-
tions in Singapore between 1st January and 31st March 2013
were included in this study. Readmission was deﬁned as any
unscheduled admission within 15 days of any discharge during
the study period.
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data were examined through the review of medical records.
Demographic data collected were age, gender, race. Patients’
race was categorized based on the 3 major ethnic groups in
Singapore, namely Chinese, Malay, and Indians. Patients
who were not placed into one of these 3 categories were classi-
ﬁed as ‘‘others’’. This categorization was important as different
ethnic groups had shown signiﬁcant differences in their health
status for the same medical condition (Hughes and Lun, 1990).
The classiﬁcation of comorbidities was taken from Charlson
Comorbidity Index (CCI) Charlson et al., 1987.
LOS was deﬁned as the number of days from the ﬁrst day
readmission till the day of discharge. It was numbered sequen-
tially and counted with day 1 being the day of readmission.
For example, if the patient was readmitted into the hospital
on 10th March 2013 and was discharged on 12th March
2013, the LOS was taken as 3 days.
The number of medications and TDD in this study was
deﬁned as the maximum number of medications and doses a
patient takes a day. This consisted of acute, chronic, prescrip-
tion, non-prescription medications, supplements, and those
medications that were to be taken when is needed, irrespective
of their dosage forms. Medications containing the same active
pharmaceutical ingredient but of different dosage forms were
considered to be different medications. For example, beta-
methasone cream and ointment applied by the same patient
would be counted as two distinct medications. Different
strengths of same medication that had the same dosing fre-
quency on different days were regarded as one medication.
Some patients took warfarin 5 mg tablets on certain days of
the week and warfarin 3 mg tablets for the remaining days.
Warfarin 5 mg and 3 mg tablets here were then counted as
one medication only. At the same time, medications such as
Alendronate that were taken once weekly were counted as
one dose.
The number of medications and TDD was obtained from
patients’ previous hospital discharge summary. If no medica-
tions had been provided in the previous discharge, the number
of chronic medications that was dispensed on the nearest date
before the previous discharge was taken into account instead.
Patients’ DRPs documented in the discharge summary were
included in this study. This documentation was done by the cli-
nicians on a voluntary basis and it was based on their clinical
judgment. The DRP classiﬁcation in this was study was
adapted from the deﬁnitions of Strand et al. (1990). They were
further broken down into smaller classiﬁcations included
hypoglycemia, hyponatremia, constipation, on top of other
DRPs such as over dosage and subtherapeutic dosage.
3.3. Analysis
STATA SE version 12.1 for Windows (Stata Corp, College
Station, TX) was used in all the statistical analyses.
Descriptive statistics were used to show patient characteris-
tics in the readmission cases collected. Characteristics such as
patients’ demographics, types of comorbidities, LOS were
expressed as mean ± standard deviation or number
(percentage).
Univariable linear regression was performed using number
of medications, TDD, demographics, types and number ofcomorbidities and types of DRPs as the independent variables
and LOS as the dependent variable. All the variables, irrespec-
tive of their p-values and signiﬁcance, were included in this
analysis in order to attain a complete picture of the relation-
ships of LOS with other variables. Earlier studies suggested
that patients aged >75 years were associated with greater risk
of hospital readmission and their readmissions were attributed
to adverse drug events, hence the age was ﬁxed at 75 year-old
in univariable linear regression to examine its association with
LOS (Chan et al., 2001; Silverstein et al., 2008).
Statistical signiﬁcance was deﬁned as p< 0.05. Indepen-
dent variables that exhibited signiﬁcant relationships in the
univariable regression were included in the multivariable linear
regression. Multivariable linear regression was performed
using LOS as the dependent variable. The number of medica-
tions and TDD was used as the independent variables in sep-
arate models. The multivariable linear regressions were
adjusted with comorbidities and DRPs as they could be con-
founding factors to the analysis. In this model, being a male,
being a Chinese, absence of comorbidities and absence of
DRP were the reference categories for gender, race, types of
comorbidities and types of DRPs respectively.
To avoid multicollinearity, care was taken to ensure that
the variance inﬂation factor (VIF) to be less than 1 in the
analysis.4. Results
Overall, 432 patients met the eligibility criteria and 649 read-
missions were evaluated for this study.
4.1. Baseline characteristics of patients
In the 649 readmission cases collected, patients were aged
67.7 ± 16.2 year-old. Majority of the patients were Chinese
(60%, n= 388), followed by Malay (19%, n= 122) and
Indian (13%, n= 85). The number of male (52%, n= 339)
and female (48%, n= 310) patients was comparable. Mean-
while, patients involved in readmission had an average of
3.33 ± 1.91 comorbidities. Hypertension, dyslipidemia and
diabetes were the main comorbidities, comprising 63%
(n= 411), 51% (n= 331) and 46% (n= 299) respectively of
the total number of readmissions.
LOS ranged from 1 to 90 days and the mean LOS was
7.63 days ± 7.08. Most of the readmission had a LOS of 2–
4 days, making up 36% (n= 233) of the total number of read-
mission events.
On average, the TDD was 18.0 ± 8.2 while the number of
medications was 10.0 ± 4.4. The main DRP encountered in
this study was non-compliance (6%, n= 36). Table 1 showed
the summary of the characteristics of readmission events
included in the analysis.
4.2. Statistical modeling
In the univariable analysis as shown in Table 2, a signiﬁcant
relationship (p< 0.05) was established between LOS during
readmission and variables of age (more than 75 year-old), race,
comorbidity (hypertension, dyslipidemia, CKD, depression),
Table 1 Characteristics of events.
Feature Total number of events (N= 649)
Age (years) 67.7 ± 16.2
Race
Chinese 388 (60)
Malay 122 (19)
Indian 85 (13)
Others 54 (8)
Gender
Male 339 (52)
Female 310 (48)
Total daily dose 18.0 ± 8.2
Number of medications 10.0 ± 4.4
Number of co-morbidities 3.3 ± 1.9
Types of co-morbidites
Diabetes 299 (46)
Hypertension 411 (63)
Dyslipidemia 331 (51)
CHD 213 (33)
COPD 41 (6)
Epilepsy 29 (4)
Asthma 63 (10)
CVA 87 (13)
CHF 33 (5)
Liver disease 50 (8)
CKD 79 (12)
Osteoarthritis 40 (6)
Osteoporosis 19 (3)
Gout 45 (7)
Cataract 39 (6)
Dementia 50 (8)
Alzheimer’s 9 (1)
Depression 53 (8)
Anemia 148 (23)
Cancer 62 (10)
BPH 41 (6)
Thyroid 33 (5)
Schizophrenia 30 (5)
Hemorrhoid 2 (1)
Hemiplegia 7 (1)
Ulcer disease 40 (6)
PKD 19 (3)
DRPs
Non-compliance 36 (6)
Hypoglycemia 6 (1)
Hyponatremia 4 (1)
Hypokalemia 4 (1)
Metabolic alkalosis 1 (1)
Dehydration 6 (1)
Low blood pressure 4 (1)
LFT abnormalities 5 (1)
Supratherapeutic dose 10 (2)
Subtherapeutic dose 1 (1)
Rashes 4 (1)
Anemia 2 (1)
Thrombocytopenia 4 (1)
N/V/D 4 (1)
Drowsiness/giddiness 5 (1)
Constipation 1 (1)
Length of stay (LOS) 7.63 ± 7.08
Table 1 (Continued)
Feature Total number of events (N= 649)
1 19 (3)
2 70 (11)
3 76 (12)
4 87 (13)
5 61 (9)
6 57 (9)
7 46 (7)
8 42 (7)
9 37 (6)
10 24 (4)
11 13 (2)
12 20 (3)
13 15 (2)
14 13 (2)
15–19 33 (5)
20–24 18 (3)
25–30 13 (2)
36–90 5 (1)
Data shown as mean ± SD or n (%).
Abbreviations: Coronary heart disease (CHD), chronic obstructive
pulmonary disease (COPD), cerebrovascular disease (CVD) benign
prostatic hyperplasia (BPH), Parkinson’s disease (PKD), liver
function test (LFT), nausea, vomiting, diarrhea (N/V/D), drug-
related problem (DRP).
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thrombocytopenia as a DRP.
In Table 3, the multiple linear regression that was adjusted
with comorbidities and DRP revealed a statistically signiﬁcant
relationship between TDD (b= 0.073, p= 0.030) and LOS.
The variables that reached signiﬁcance included age more than
75 year-old (b= 1.547, p= 0.008), Malay (b= 1.512,
p= 0.033), race of others (b= 2.617, p= 0.007), depression
as a comorbidity (b= 2.155, p= 0.031) and thrombocytope-
nia as a type of DRP (b= 7.554, p= 0.027). When TDD
was substituted by the number of medications, the same vari-
ables remained signiﬁcant, namely, number of medications
(b= 0.148, p= 0.021), age more than 75 year-old
(b= 1.530, p= 0.009), Malay (b= 1.468, p= 0.038), race
of others (b= 2.6499, p= 0.007), depression as a comorbid-
ity (b= 2.195, p= 0.028) and thrombocytopenia as a type of
DRP (b= 7.5260, p= 0.028).5. Discussion
This study identiﬁed that TDD was signiﬁcantly associated
with LOS in both univariable (b= 0.116, p= 0.001) and mul-
tiple linear regression (b= 0.073, p= 0.030). Earlier studies
found that the number of medications was unassociated with
LOS (Nobili et al., 2011; Schuler et al., 2008). However, our
results suggested otherwise in both univariable (b= 0.241,
p< 0.001) and multiple linear regression (b= 0.148,
p= 0.021) as polypharmacy contributed substantially to
patients’ LOS upon their readmission. This difference may
be because we included both prescription and over-the-counter
(OTC) medications in our study while earlier studies only took
Table 2 Univariable regression with duration of readmissions and variables.
Duration of readmissions
Variables b (·102) 95% CI (·102) P value
Total daily dose 11.65 5.01, 18.29 0.001
Number of medications 24.14 11.96, 36.33 <0.001
Age (more than 75 year-old) 206.02 94.63, 317.41 <0.001
Racea
If Malay 215.53 358.48, 72.57 0.003
If Indian 175.48 340.42, 10.54 0.037
If others 285.96 486.00, 85.92 0.005
Genderb
If female 150.2 41.44, 258.95 0.007
Co-morbiditiesc
Diabetes 21.59 131.18, 88.00 0.699
Hypertension 193.13 80.75, 305.51 0.001
Dyslipidemia 110.91 1.95, 219.86 0.046
CHD 20.11 96.23, 136.46 0.734
CVA 158.98 0.90, 318.86 0.051
CHF 220.45 27.65, 468.56 0.081
COPD 137.91 86.41, 362.23 0.228
Asthma 159.96 344.09, 24.16 0.088
Liver disease 129.46 334.09, 75.18 0.215
CKD 203 36.65, 369.35 0.017
Osteoarthritis 67.65 294.77, 159.47 0.559
Osteoporosis 22.02 346.10, 302.06 0.894
Gout 115.65 99.24, 330.53 0.291
Cataract 30.67 199.20, 260.54 0.793
Anemia 46.43 83.73, 176.59 0.484
Cancer 154.5 30.97, 339.98 1.64
BPH 20.76 203.81, 245.32 0.856
Thyroid disease 102.33 146.24, 350.89 0.419
Hem 638.49 345.96, 1622.93 0.203
Epilepsy 149.47 413.65, 114.70 0.267
Dementia 171.75 32.70, 376.20 0.1
Depression 282.21 83.90, 480.51 0.005
Alzheimer’s disease 154.51 621.55, 312.52 0.516
Schizophrenia 66.25 193.90, 326.39 0.617
PKD 173.17 150.64, 496.97 0.294
Hemiplegia 8.03 520.88, 5.36.95 0.976
Ulcer disease 57.00 284.13, 170.14 0.622
Number of comorbidities 42.50 14.11, 70.88 0.003
Types of DRPd
Non-compliance 138.65 99.79, 377.10 0.254
Hypoglycemia 350.05 920.26, 220.16 0.228
Hyponatremia 231.63 1037.40, 574.14 0.573
Hypokalemia 13.57 1000.71, 973.58 0.978
Metabolic alkalosis 163.73 1556.56, 1229.09 0.818
Dehydration 322.84 247.47, 893.14 0.267
Low blood pressure 265.12 962.88, 432.64 0.456
Giddiness 36.8 588.04, 661.64 0.908
LFT abnormalities 38.51 658.70, 735.71 0.914
N/V/D 112.21 585.80, 810.22 0.752
Constipation 236.88 1155.88, 1629.65 0.739
Anemia 638.49 345.96, 1622.93 0.203
Thrombocytopenia 841.71 146.68, 1536.74 0.018
Rashes 214.81 912.67, 483.06 0.546
Supratherapeutic dose 296.48 257.12, 850.08 0.293
Subtherapeutic dose 437.19 955.29, 1829.67 0.538
Abbreviations: Coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD) benign prostatic
hyperplasia (BPH), Parkinson’s disease (PKD), liver function test (LFT), nausea, vomiting, diarrhea (N/V/D), not signiﬁcant (NS); p> 0.05,
drug-related problem (DRP).
a Chinese as reference group.
b Male as reference group.
c Absence of comorbidities as reference group.
d Absence of DRP as reference group.
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Table 3 Multiple linear regressions with duration of readmissions and total daily dose or number of medications after adjustments
with covariates.
Duration of readmissions
Variables b (·102) 95% CI (·102) P value b (·102) 95% CI (·102) P value
Total daily dose 7.33 0.71, 13.94 0.03 NA NA NA
Number of medications NA NA NA 14.87 2.26, 27.47 0.021
Age (more than 75 year-old) 154.77 40.43, 269.11 0.008 153.03 38.67, 267.40 0.009
Racea
If Malay 151.23 290.32, 12.13 0.033 146.87 285.75, 7.98 0.038
If Indian 104.62 270.23, 61.00 0.215 106.48 272.02, 59.06 0.207
If others 261.74 452.73, 70.74 0.007 264.99 455.96, 74.02 0.007
Genderb
If female 91.54 14.71, 197.78 0.091 89.68 16.58, 195.94 0.098
Co-morbiditiesc
HTN 95.15 27.62, 217.93 0.129 82.5 41.62, 206.62 0.192
HLD 13.25 102.44, 128.94 0.822 6.6 109.57, 122.76 0.911
CKD 161.29 0.72, 323.30 0.051 157.08 5.19, 319.35 0.058
Depression 215.51 19.90, 411.12 0.031 219.51 24.16, 414.86 0.028
Types of DRPd
Supratherapeutic dose 292.26 246.23, 830.74 0.287 268.88 270.31, 808.07 0.328
Thrombocytopenia 755.48 84.25, 1426.71 0.027 752.6 81.70, 1423.51 0.028
Abbreviations: Drug-related problem (DRP).
a Chinese as reference group.
b Male as reference group.
c Absence of comorbidities as reference group.
d Absence of DRP as reference group.
Total Daily Doses and length of stay 393prescription medications into consideration. As the exclusion
of OTC medications was suspected to cause the underestima-
tion of the total number of medications taken by the popula-
tion in other studies, OTC medications were counted to
better reﬂect the actual pill burden of the patients (Bjerrum
et al., 1998). In addition to the potential adverse consequences
such as DRPs and unintended hospital admissions attributed
to OTC medications, there is a high prevalence of concurrent
use of both prescription and OTC medications (Eickhoff
et al., 2012; Qato et al., 2008). Hence, it was essential to esti-
mate their effects on LOS. This study provided signiﬁcant
insights into the association between pill burden and LOS.
To date, the majority of studies on LOS focus on polyphar-
macy and DRPs, this study was the ﬁrst to associate the
LOS with TDD as well as the number of medications
(Nobili et al., 2011; Qato et al., 2008; Gorard, 2006). On top
of other implications caused by polypharmacy, this ﬁnding
would prompt clinicians to use the least possible number of
TDDs and medications (Salazar et al., Nov 2007; Fulton and
Riley Allen, 2005).
In this study, patients’ LOS could be attributed to DRPs
caused by high TDD. Due to the nature of a retrospective
study, there may be an underestimation of DRPs, causing
most of the DRPs to be non-signiﬁcantly related to LOS.
However, as earlier studies had demonstrated that DRPs
increase patients’ LOS in the hospital, DRPs could still be
a plausible link for this association between TDD and
LOS in this study (Moura et al., 2009; Reducing and
Preventing Adverse Drug Events To Decrease Hospital
Costs, 2001).The multiple linear regressions for the total number of
readmissions revealed racial category of Malay and others
(encompassed Eurasians, Sinhalese and other minority races)
to be signiﬁcantly associated with LOS. Consistent with the
ﬁndings from other studies, racial disparity was common in
other populations and this had been highlighted (Cook et al.,
2006; Hlaing, 2007; de Bruijne et al., 2013). In a European
study, researchers found that non-Western ethnic groups had
a higher risk for increased LOS as compared to ethnic Dutch
patients (de Bruijne et al., 2013). Therefore, clinicians may
have to take ethnicity into consideration when examining
patients’ health outcomes and estimating their LOS.
As mentioned by Uldall et al., there is a signiﬁcant correla-
tion between psychological comorbidity and LOS (Uldall
et al., 1994). In the present study, depression as a comorbidity
had a signiﬁcant relationship with LOS and this was shown in
both univariable and multiple linear regressions. This correla-
tion was conﬁrmed by prior studies where psychiatric comor-
bidity increased patients’ average LOS (Uldall et al., 1994;
Saravay et al., 1991; Verbosky et al., 1993). Thus, clinicians
who are attending to psychiatric patients should be prepared
for the possibility of prolonged LOS.
LOS was associated to having thrombocytopenia as a DRP
in both univariable and multiple linear regressions. Literatures
from the United States and Canada had also documented that
patients suffering from thrombocytopenia could have long
LOS in the hospital or more speciﬁcally the specialized units
(Cawley et al., 1999; Crowther et al., 2005). This ﬁnding would
caution clinicians of the increased risk of prolonged LOS if
their patients have DRPs, in particular thrombocytopenia.
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Similar to other retrospective studies where important data
may not be available, there was an absence of the severity of
comorbidities in this study (Hess, 2004). Comorbidities such
as hypertension and diabetes that were shown to be associated
with patients’ LOS in earlier study did not demonstrate signif-
icant association (Thombs et al., 2007). Only depression as
comorbidity was signiﬁcantly associated to LOS. Therefore,
this study failed to conﬁrm the statistical signiﬁcance between
comorbidities and LOS that were detected by other studies at
the multiple linear regression level (Rochon et al., 1996). Sim-
ilarly, while the complexity and severity of the patients’ condi-
tions upon admission were recognized to be a major
determining factor of LOS, this information could be not be
clearly accounted for in this study (Berki et al., 1984). Notably,
this was a common issue seen in risk prediction models for
hospital readmissions as limited studies evaluated illness sever-
ity (Kansagara et al., 2011).
Besides, the deﬁnitions of the different types of DRPs were
not standardized. The difference in the deﬁnitions of DRPs
such as non-compliance could lead to variations in the study
outcomes (Cleemput et al., 2002). Without standardized
deﬁnitions of DRPs, clinicians could have failed to record
the possible DRPs. This could potentially lead to an underes-
timation of the cases related to DRP.
The LOS in this study was taken from the readmissions
within 15 days of discharge, while many other studies adopted
30-day readmission (Kansagara et al., 2011). Hence, fewer
events were included in this study as compared to other studies
on LOS (Nobili et al., 2011; Classen et al., 1997). While Fine
et al’s study on LOS numbered it by representing the day of
admission as day 0, this study numbered the day of admission
as day 1 (Fine et al., 2000). As such, the deﬁnition of LOS was
either unclear or absent in a number of studies on LOS (Nobili
et al., 2011; Campbell et al., 2004; Incalzi et al., Mar 1992;
Moura et al., 2009; Rochon et al., 1996). Although this devia-
tion and ambiguity in the deﬁnition may potentially introduce
discrepancies in the results, this difference was assumed to be
negligible till other studies prove otherwise.
5.2. Implications
This is the ﬁrst study to use TDD to investigate the effect of
patients’ pill burden on their LOS and to establish signiﬁcant
association between TDD and LOS. As far as we know, there
had been scant information on the association between num-
ber of medications and LOS and there had been no signiﬁcant
associations found (Nobili et al., 2011; Schuler et al., 2008).
This study however yielded a signiﬁcant relationship between
numbers of medications and LOS when all the medications
(prescription, non-prescription, chronic, acute) were included.
Hence, this study introduced a new dimension to the current
studies on LOS and polypharmacy as pill burden in terms of
TDD was taken into account. TDD is a legitimate concern
and important variable to look into. As dosing frequency is
known to be one of the main barriers to adherence, less fre-
quent dosing is encouraged (Ingersoll and Cohen, 2008;
Haynes et al., 2002; McDonald et al., 2002). This ﬁnding
would motivate clinicians to take TDD into serious consider-
ations when they prescribe or carry out medical reconciliation.TDD reduction could be achieved through the use of
extended release formulation or combination drugs. This had
been reported to minimize patients’ risk of taking duplicate
medications, enhance their symptomatic control for certain
disease states as well as to improve their compliance (Richter
et al., 2003; Bae et al., 2012; Paes et al., 1997). TDD reduction
and better compliance could translate into reduced healthcare
resource utilization and costs (Richter et al., 2003; Toy et al.,
2011). However, TDD reduction also presented potential dis-
advantages. Though these modiﬁed products reduce TDD,
they were associated with delayed achievement of pharmaco-
dynamics effect and sustained toxicity (Prisant and Elliott,
2003; Ranade, 1991). At the same dosing, the effectiveness of
the treatment could be compromised when TDD is reduced.
Malo et al. reported that administering budesonide on a four
times daily basis instead of twice daily was more effective in
controlling asthma, although patients were less compliant
and were exposed to more adverse effects (Malo et al., 1995).
Certain medications may also be inappropriate for reduced
dosing frequency because possible adverse events could be cul-
minated from their pharmacokinetic and pharmacodynamics
(Richter et al., 2003).
Future prospective studies are warranted to examine the
signiﬁcance of TDD reduction based interventions on the
improvement of patients’ LOS. In view of the implications of
polypharmacy, it was initially hypothesized in this study that
DRP was the cause of the signiﬁcant relationship between
TDD and LOS (Moura et al., 2009; Reducing and
Preventing Adverse Drug Events To Decrease Hospital
Costs, 2001). Although this study did not show that DRP
was the link in the association between TDD and LOS, this
introduced a room for future prospective studies with stan-
dardized deﬁnition of DRPs to conﬁrm this hypothesis.
6. Conclusion
We conclude that TDD before patient’s readmission had a sig-
niﬁcant association with patients’ LOS upon readmission.
Medication regimen simpliﬁcation through approaches such
as the use the extended release products could be considered
to minimize patients’ DRP and their LOS.
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